Skip to main content

Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Table 6 Time to events for elevations in hepatic transaminases and APTC events (Safety Population)

From: Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: A randomised controlled trial in patients with osteoarthritis

  Lumiracoxib 100 mg o.d. (n = 755) Lumiracoxib 100 mg b.i.d. (n = 1,519) Celecoxib 200 mg o.d. (n = 758)
Time interval (days) No. of subjects with events within the interval Incidence rate within the interval (%) No. of subjects with events within the interval Incidence rate within the interval (%) No. of subjects with events within the interval Incidence rate within the interval (%)
AST/ALT >3 × ULN
   1 – 49 0 0.00 4 0.26 1 0.13
   50 – 105 1 0.15 7 0.53 1 0.15
   106 – 196 6 1.15 18 1.64 1 0.19
   197 – 287 3 0.76 5 0.63 0 0.00
   >287 1 0.28 1 0.14 0 0.00
Definite/probable APTC events
   1 – 49 0 0.00 1 0.07 0 0.00
   50 – 105 0 0.00 1 0.07 1 0.13
   106 – 196 1 0.13 1 0.07 0 0.00
   197 – 287 1 0.13 3 0.20 1 0.13
   >287 1 0.13 0 0.00 0 0.00
  1. o.d. = once daily; b.i.d. = twice daily.